The United States is a party to the 1971 Convention on Psychotropic Substances, which states that a member state (like the U.S.A.) may contribute information regarding a banned substance, such as cannabis and its cannabinoids, to the UN Secretary General to allow the WHO to reconsider its previous position on the substance. There are 16 substances presently under review by the WHO, including cannabis and its resins, extracts, etc., including CBD, which is not mentioned in the Convention on Psychotropic Substances. Essentially, the FDA is laying the groundwork to eventually reschedule CBD. Because the notice regards cannabis and its extracts, resins, tinctures and specifically lists Delta-9 THC, we have the opportunity to comment on both.
Submit public comment online here or mail no later than October 31, 2018 at 11:59 EST:
Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
Make sure to include the following information (cut & paste) for mail-in submissions: Docket No. FDA-2018-N-3685 for “International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; ADB-FUBINACA; FUB-AMB(MMB-FUBINACA_AMB-FUBINACA); ADB-CHMINACA; CUMYL-4CN-BINACA; Cyclopropyl Fentanyl; Methoxyacetyl Fentanyl; Ortho-Fluorofentanyl; Para- Fluoro Butyrfentanyl; Para-Methoxybutyrfentanyl; N-Ethylnorpentylone; Tramadol; Pregabalin; Cannabis Plant and Resin; Extracts and Tinctures of Cannabis; Delta-9-Tetrahydrocannabinol; Stereoisomers of Tetrahydrocannabinol; Request for Comments.